KCM
PCRX icon

Kennedy Capital Management’s Pacira BioSciences PCRX Stock Holding History

Kennedy Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-97,000
Closed -$4.43M – 756
2017
Q4 		$4.43M Sell
97,000
-1,133
-1% -$44.9K 0.08% 463
2017
Q3 		$3.69M Buy
+98,133
New +$3.95M 0.07% 516
2017
Q1 		– Sell
-47,643
Closed -$1.54M – 752
2016
Q4 		$1.54M Sell
47,643
-2,181
-4% -$72.8K 0.03% 633
2016
Q3 		$1.71M Buy
+49,824
New +$1.95M 0.03% 599
2015
Q3 		– Sell
-24,931
Closed -$1.76M – 738
2015
Q2 		$1.76M Buy
+24,931
New +$1.96M 0.03% 611

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Kennedy Capital Management's PCRX Position: Q1 2018 in Review

Kennedy Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2018, closing a stake of 97,000 shares — an estimated $4.43M sold.

Kennedy Capital Management first reported a position in PCRX in Q2 2015 and held it in 5 quarters. The position peaked at $4.43M in Q4 2017. 168 funds tracked by Wall St. Rank hold PCRX as of Q1 2018.

  • Kennedy Capital Management reported no remaining Pacira BioSciences position as of Q1 2018 after selling out during the quarter.
  • Kennedy Capital Management sold 97,000 Pacira BioSciences shares in Q1 2018, an estimated $4.43M.
  • Kennedy Capital Management first reported a position in Pacira BioSciences in Q2 2015 and held it in 5 quarters.
  • Kennedy Capital Management's Pacira BioSciences position peaked at $4.43M in Q4 2017.
  • 168 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2018.

Based on Kennedy Capital Management's 13F filing for Q1 2018, filed 14 May 2018.